Ann: Results of Phase 2 Clinical Trial, page-84

I am sorry to hear of your loss. It is good that you are aware of the important things in life and that money is not everything.

FTT as a shell is, IMO, as good as they come. As the directors are not taking a salary, pipeline is on hold and existing trial costs will cease, the burn on this will be low. The cash should last some time and they may also get a decent amount of R&D refund back.

It will also be in the board's best interest to find a deal reasonably quickly so they are not going unpaid for too long. So I would hold as this could recover depending on the deal, back to a $10m+ market cap on initial euphoria.